Evaluation of the antihypertensive effect of perindopril-amlodipine fixed dose combination - Perindopril-amlodipine reducing blood pressure level trial: PEARL study;A perindopril-amlodipin fix kombináció vé rnyomáscsökkento hatásának vizsgálata A PEARL tanulmány

Lege Artis Medicinae

Volumn 20, Issue 8, 2010, Pages 499-507

  Viktor, Nagy ^a   Éva, Lantos ^b   Norbert, Habony ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Egis Nyrt ^*  (Hungary)

Author keywords

Efficacy; Hypertension; Perindopril amlodipin fix combination; Target blood pressure; Tolerability

Indexed keywords

EID: 77956763063     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-9.
2. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009;27:963-75.
3. Danon-Hersch N, Marques-Vidal P, Bovet P, Chiolero A, Paccaud F, Pécoud A, et al. Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study. Eur J Cardiovasc Prev Rehabil 2009;16:66-72.
4. Leenen FH, Dumais J, Mclnnis NH, Turton P, Stratychuk L, Nemeth K, et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008;178:1441-9.
5. Széles G, Vokó Z, Jenei T, Kardos L, Pocsai Z, Bajtay A, et al. A preliminary evaluation of a health monitoring programme in Hungary. Eur J Public Health 2005;15:26-32.
6. Nagy V, Horváth A, Molnár K, Blaskó Gy, de Châtel R.; az EMMA vizsgálócsoport nevében. Magyarországi magasvérnyomás-vizsgálat - EMMA. LAM 2003;13:32-40.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo L Jr, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560-72.
8. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
9. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertension 2009;27:2121-58.
10. A Magyar Hypertonia Társaság Szakmai Irányelvek Bizottsága. A hypertoniabetegség felnottkori és gyermekkori kezelésének szakmai és szervezeti irányelvei. Hypertonia és Nephrologia 2009;13: (S2) 89-168.
11. Hurst M, Jarvis B. Perindopril: an updated review of its use in hypertension. Drugs 2001;61:867-96. (Pubitemid 32509594)
12. Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009;30:1385-94.
13. Tyler HM. Amlodipine: an effective once-daily antihypertensive agent. J Hum Hypertens 1991;5(Suppl 1):61-6.
14. Brener SJ, Ivanc TB, Poliszczuk R, Chen M, Tuzcu EM, Hu T, et al. Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Am Heart J 2006;152:1059-63.
15. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
16. Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Deckers JW, Fox KM; EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J 2010;159:795-802.
17. A Magyar Hypertonia Társaság Méréstechnikai Munkacsoportja. A vérnyomás mérése. Hypertonia és Nephrologia 2006;10(Suppl 2):15-26.
18. Lefrandt JD, Heitmann J, Sevre K, Castellano M, Hausberg M, Fallon M, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001;14:1083-9.
19. Dendorfer A, Raasch W, Tempel K, Dominiak P. Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res Cardiol 1998;93(Suppl 2):24-9.